Argent Biopharma Limited PDMR Notification
April 10 2024 - 11:30AM
RNS Regulatory News
RNS Number : 0885K
Argent Biopharma Limited
10 April 2024
Argent BioPharma
Ltd
PDMR
Notification
10 April
2024
ASX, LSE:
RGT
Argent BioPharma Ltd ('Argent BioPharma'
or 'the
Company') wishes to advise that the
following Persons Discharging Managerial Responsibilities
(PDMR) have dealt with
shares in Argent BioPharma, and this notification is made in
accordance the UK Market Abuse Regulations.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
(a)
|
Name
|
Amir Polak
|
|
2
|
Reason for the notification
|
|
(a)
|
Position
|
Chief Pharmaceutical Development
Officer
|
|
(b)
|
Initial
notification/amendment
|
Initial
|
|
(c)
|
If amendment: reason
|
n/a
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Full name of entity
|
Argent BioPharma Limited
|
|
|
Legal Entity Identifier
Code
|
213800HRE3FQJ6RK4H10
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; (iv) each place where transactions have been
conducted
|
|
(a)
|
Description of the financial
instrument, type of instrument
|
Fully Paid Ordinary Shares
|
|
(b)
|
Identification Code (ISIN)
|
AU0000326647
|
|
(c)
|
Nature of transaction
|
Disposal of Shares
|
|
(d)
|
Currency
|
Price
|
Volume
|
Total
|
|
|
AUD
|
0.43
|
200
|
86.00
|
|
|
AUD
|
0.43
|
3,300
|
1,419.00
|
|
|
AUD
|
0.44
|
2,000
|
880.00
|
|
|
Aggregated
information
|
|
|
AUD
|
|
5,500
|
2,385.00
|
|
(e)
|
Date of transaction
|
8-10 April 2024
|
|
(f)
|
Place of transaction
|
On Market
|
|
|
|
|
|
| |
-Ends-
Authorised for release by the Company Secretary, for further
information please contact:
About Argent
BioPharma
Argent BioPharma is dedicated to
meeting unmet medical needs by combining PolyPharmacology and
Nanotechnology, aspiring to be a renowned global leader in the
biopharmaceutical sector. Our mission centres on researching and
developing ground-breaking treatments for worldwide health issues,
guided by strategic principles such as pioneering life science
advancements, ensuring global access, fostering continuous
innovation, and striving for industry leadership.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHZZGMDKGLGDZM
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Apr 2023 to Apr 2024
